Maxim's Strong Incentive..., page-38

Drafter, I thnk only cohort four could underwhelm. Market will be looking for response and it might not be there at all. Something should definitely happen in four, then if it doesn't it spells trouble.

I believe the vector will be tweaked anyway. For the HBV and for the phase 2B. TT-034 will work well enough to warrant 2B......IMO.

By the way, an efficacy report doesn't mean they are expecting a response. Efficacy of the concept so far IE safety and transduction.